You are here

EASD

EASD 2022 – Pfizer’s oral GLP-1s struggle for a therapeutic window

EP Vantage

Fri, 09/23/22 - 10:34 am

EASD: AstraZeneca piles on supporting evidence for Farxiga use in heart failure

Fierce Pharma

Thu, 09/19/19 - 07:59 pm

Novo and Sanofi make case for hypo-reducing insulins at EASD

Pharmaforum

Thu, 09/19/19 - 09:59 am

EASD: Novo's Ozempic tops Victoza, J&J's Invokana in double head-to-head win

Fierce Pharma

Tue, 09/17/19 - 03:41 pm

EASD: Lilly, BI tout new Jardiance kidney analysis as rival J&J nears FDA nod

Fierce Pharma

Tue, 09/17/19 - 11:00 am

Boehringer Ingelheim

Severe hypoglycemia multiplies death risk up to fourfold in diabetes, Novo Nordisk finds

Fierce Pharma

Fri, 09/15/17 - 11:19 am

AstraZeneca's Bydureon fails to show cardio-protection

BioPharma Dive

Thu, 09/14/17 - 10:05 pm

EASD: Boehringer Ingelheim, Lilly's Jardiance holds CV benefit regardless of blood sugar starting point

Fierce Pharma

Thu, 09/14/17 - 11:27 am

Boehringer Ingelheim

EASD: AstraZeneca's Farxiga cuts blood sugar, weight and insulin use in Type 1 study

Fierce Pharma

Thu, 09/14/17 - 09:56 am

EASD: Sanofi's Toujeo bests Lantus at holding off hypoglycemia, studies show

Fierce Pharma

Thu, 09/14/17 - 09:45 am

EASD: Novo Nordisk's combo Xultophy beat rivals at cutting LDL, blood pressure

Fierce Pharma

Wed, 09/13/17 - 10:57 am

LDL cholesterol

Novo Nordisk's Data at EASD

Yahoo/Zacks.com

Thu, 09/15/11 - 11:51 am